Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC Tolerable Safety Profile Consistent with Prior Clinical Trial … [Read more…]

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with a median maximal cognitive decline of -15.8% for NUBEQA versus -36.1% with enzalutamide (p=0.009) in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic … [Read more…]

Robust enrollment of 173 patients across dose escalation and expansion cohorts, with objective responses observed across five tumor types JK06 continued to demonstrate a highly differentiated MMAE safety profile with predominantly low-grade, manageable treatment-related adverse events (TRAEs) at doses selected for expansion cohorts Objective response rate (ORR) of 50% (5 of 10) among response-evaluable squamous … [Read more…]

– Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) – Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment of chronic hepatitis delta virus (HDV), including in patients with advanced disease – Treatment with LIVMARLI® (maralixibat) demonstrates improved event-free … [Read more…]

Sentinel Agents™, NexusPulse™ Intelligent Calculators, DrArturo AI™, Phoebe AI™, Patient Connect™, and TrialRelay™ create a real-time multi-agent orchestration layer for precision oncology access CHICAGO–(BUSINESS WIRE)–Massive Bio today announced the next-generation product suite within Reticulum Nexus™, introducing a coordinated set of AI agents, intelligent calculators, signal engines, patient navigation tools, and physician referral workflows designed to … [Read more…]

The new voice chat AI assistant, Clara, provides 24/7 bilingual support to streamline inbound calls, handle common questions and reduce on-hold times. CARROLLTON, Ga.–(BUSINESS WIRE)–Tanner Health, a leading nonprofit healthcare system serving west Georgia and east Alabama, today announced its go-live with Hyro, the leading Responsible AI Assistant Platform for health care, to streamline patient … [Read more…]

Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement Study shows for the first time, based on the Prosigna test results, that more than two-thirds of patients could be spared chemotherapy without compromising outcomes SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VCYT #ASCO26–Veracyte, … [Read more…]

Enables ultra-sensitive molecular disease detection, with high specificity Provides accelerated results, with the personalized tumor fingerprint and initial blood test expected within approximately 2 to 3 weeks from the sample receipt, and subsequent blood test results anticipated within 1 to 3 days BOSTON–(BUSINESS WIRE)–Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced the … [Read more…]

Curebound’s annual benefit concert with headliner P!NK raises over $8.25 million in one night for cancer research, joining a roster of past headliners that includes Elton John, Ed Sheeran and Alicia Keys. SAN DIEGO–(BUSINESS WIRE)–#CancerResearch—Curebound, a cancer research accelerator, today announced that its 2026 Concert for Cures, headlined by global music icon P!NK, raised $8.25 … [Read more…]

TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of … [Read more…]